Consensus Pharmacological Interactions for PLK2 Inhibitor Identification in Colorectal Cancer Treatment
Background and Purpose Polo-like kinase 2 (PLK2) is a critical regulator of cellular stress responses, redox balance, and tumour progression. In colorectal cancer (CRC), elevated PLK2 expression promotes chemoresistance and poor prognosis by modulatin
Authors
- CHENG-CHIH CHUNG
- Shih‐Chung Yen (ORCID: https://orcid.org/0000-0001-8596-0083)
- Kai‐Cheng Hsu (ORCID: https://orcid.org/0000-0002-9022-6673)
- Tony Eight Lin (ORCID: https://orcid.org/0000-0002-6267-0224)
- Yun‐Hsuan Yeh (ORCID: https://orcid.org/0000-0002-8983-6300)
- Jui-Hua Hsieh
- Shiow‐Lin Pan (ORCID: https://orcid.org/0000-0001-7449-3539)
- Chunlin Yang (ORCID: https://orcid.org/0000-0001-9350-343X)
- Yi-Wen Wu (ORCID: https://orcid.org/0000-0002-6625-0630)
- Tzu-Ying Sung
- Yu-Ting Fang-Chin (ORCID: https://orcid.org/0009-0002-0634-7104)
Institutions
- National Institute of Environmental Health Sciences (US)
- Chinese University of Hong Kong, Shenzhen (CN)
- Drug Discovery Laboratory (Norway) (NO)
- Taipei Medical University (TW)
Publication Details
- Published
- 2025-08-22
- DOI
- https://doi.org/10.22541/au.175584841.11099249/v1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00